Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionBernardo Rodríguez–Martín, Adrian Baez‐Ortega, Fran Supek et al.|Nature Genetics|2020Cited by 479
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Sydney X. Lu et al.|JAMA Oncology|2021Cited by 119
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95
Pan-cancer analysis of whole genomes reveals driver rearrangements promoted by LINE-1 retrotransposition in human tumoursBernardo Rodríguez–Martín, Peter J. Campbell, Eva G. Álvarez et al.|bioRxiv (Cold Spring Harbor Laboratory)|2017Cited by 18
Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionBernardo Rodríguez–Martín, Eva G. Álvarez, Jorge Zamora et al.|Nature Genetics|2023Cited by 5